Cas12 Protein Market Report Size, Forecast to 2035

How Much Growth Is Anticipated In The Cas12 Protein Market Size From 2026 To 2035?
The cas12 protein market size has grown rapidly in recent years. It will grow from $2.26 billion in 2025 to $2.62 billion in 2026 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to early adoption of crispr-cas technologies, increasing academic research in gene editing, rising demand for molecular biology tools, growth in genetic engineering studies, availability of basic cas12 protein variants.

The cas12 protein market size is expected to see rapid growth in the next few years. It will grow to $4.65 billion in 2030 at a compound annual growth rate (CAGR) of 15.4%. The growth in the forecast period can be attributed to expansion of crispr-based diagnostics, development of advanced delivery methods, increasing investment in gene therapies, growing pharmaceutical and biotechnology r&d spending, rising regulatory approvals for crispr-based therapeutics. Major trends in the forecast period include growing use of cas12 in rapid molecular diagnostics, rising adoption of cas12 for precise genome editing, increasing development of modified and high-fidelity cas12 variants, expansion of cas12 applications in therapeutics development, rising demand for lyophilized and stable cas12 formulations.

Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27240&type=smp

What Essential Growth Drivers Are Pushing The Cas12 Protein Market Forward?
The increasing prevalence of genetic diseases is expected to propel the growth of the Cas12 protein market going forward. Genetic diseases are disorders caused by changes or mutations in an individual's DNA that affect normal body functions. The increasing genetic diseases are due to the rising rate of consanguineous marriages, which increases the likelihood of inheriting genetic disorders. Cas12 protein targets and cuts DNA at specific sites to correct, remove, or replace faulty genes, enabling precise gene therapies for inherited disorders with high accuracy and minimal off-target effects. For instance, in July 2025, according to the National Blood Authority, an Australia-based blood management agency, there were 2,788 patients living with hereditary haemophilia A (HMA) in 2023–2024, up from 2,681 patients in 2022–2023. Therefore, the increasing prevalence of genetic diseases is driving the growth of the Cas12 protein market.

Which Segment Groups Play A Crucial Role In Outlining The Cas12 Protein Market’s Structure?
The cas12 protein market covered in this report is segmented –

1) By Type: Natural Cas12 Proteins, Modified Cas12 Proteins, Integration With Other CRISPR Components
2) By Formulation: Liquid Formulations, Lyophilized Powder, Plasmid-Derived Cas12 Proteins
3) By Delivery Method: Viral Vectors, Lipid Nanoparticles, Electroporation, Microinjection
4) By Application: Genome Editing, Gene Knockout, Gene Regulation, Genetic Engineering, Therapeutics Development
5) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Agricultural Companies

Subsegments:
1) By Natural Cas12 Proteins: Cas12a, Cas12b, Cas12c
2) By Modified Cas12 Proteins: Engineered Cas12 Variants, High-Fidelity Cas12 Proteins, Fusion Proteins With Cas12
3) By Integration With Other CRISPR Components: Cas12 With Cas9 Systems, Cas12 With Base Editors, Cas12 With Prime Editors

What New Trends Are Beginning To Take Shape Within The Cas12 Protein Market?
Major companies operating in the Cas12 protein market are focusing on developing advanced solutions, such as equity investment, to accelerate innovation and expand their gene-editing capabilities. Equity investment refers to the process of investing money by purchasing shares or ownership stakes in a company, giving the investor partial ownership and potential returns based on the company’s performance. For instance, in April 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, invested $100 million in Mammoth Biosciences to access their ultracompact CRISPR enzymes for delivering in vivo gene editing therapies using adeno-associated viruses (AAVs) to multiple tissues beyond the liver. These companies combine Mammoth’s ultracompact CRISPR enzymes with its advanced AAV delivery system for targeted gene therapies beyond the liver. These smaller enzymes fit within AAV vectors, enabling precise and efficient in vivo editing. The partnership offers Mammoth major funding, milestones, and royalties, while Regeneron gains exclusive access to cutting-edge tools for over five years. Together, they aim to accelerate next-generation genetic medicines for a wider range of diseases.

Which Companies Represent The Key Strategic Forces Within The Cas12 Protein Market?
Major companies operating in the cas12 protein market are Thermo Fisher Scientific Inc., Bio-Techne Corporation, Integrated DNA Technologies Inc., GenScript Biotech Corporation, Takara Bio Inc., Aldevron LLC, New England Biolabs Inc., Synthego Corporation, Mammoth Biosciences Inc., Editas Medicine Inc., VectorBuilder, Sherlock Biosciences, Inscripta Inc.

Get Your In-Depth Cas12 Protein Market Report Now:
https://www.thebusinessresearchcompany.com/report/cas12-protein-global-market-report

Which Regional Clusters Are Forecasted To Outperform Others In The Cas12 Protein Market?
North America was the largest region in the Cas12 protein market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cas12 protein market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company